Brought to you by 
Syntimmune closes first $8mm tranche of $26mm Series A round; adds additional tranches
21 Jun 2017
Executive Summary
Immune disease start-up Syntimmune Inc. raised $8mm through the first tranche of its committed $26mm Series A round. Apple Tree Partners and Baxalta Ventures co-led and were joined by additional undisclosed investors.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Syntimmune closes first $8mm tranche of $26mm Series A round; adds additional tranches
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice